RxSight reports Q1 adjusted EPS (3c), consensus (8c)

Reports Q1 revenue $37.9M, consensus $37.91M. “The exceptional clinical value delivered by our Light Adjustable Lens continues to drive significant enthusiasm among cataract surgeons,” said Ron Kurtz, Chief Executive Officer and President of RxSight (RXST). “The excitement and engagement we observed at the recent ASCRS meeting further reinforces our conviction that customization and post-operative adjustability are shaping the future of premium cataract surgery. Supported by strong customer and patient interest, an innovative product pipeline, the expansion of third-party light treatment service center business models, and recent international regulatory approvals, we believe we are well-positioned to lead the next chapter of growth in the premium IOL market.”